13.21MMarket Cap-2115P/E (TTM)
13.170High11.760Low33.15KVolume12.450Open12.890Pre Close413.19KTurnover5.83%Turnover RatioLossP/E (Static)1.07MShares32.55052wk High3.31P/B7.04MFloat Cap5.40052wk Low--Dividend TTM568.58KShs Float101.250Historical High--Div YieldTTM10.94%Amplitude5.400Historical Low12.465Avg Price1Lot Size
Cadrenal Therapeutics Stock Forum
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
Cadrenal Therapeutics (Nasdaq: CVKD) highlighted a recently published manuscript in the Journal of Cardiac Failure, evaluating the relationship between time in therapeutic range (TTR) management quality and clinical outcomes for left ventricular assist device (LVAD) patients. The findings emphasize the need for improved anticoagulation th...
Larger Image: tradingview.com...
$Cadrenal Therapeutics (CVKD.US)$
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
Cadrenal Therapeutics (Nasdaq: CVKD) has presented new data from the ARIES-HM3 trial at the ISHLT conference, showing the significant impact of anticoagulation quality in LVAD patients. The trial highlighted the deficiencies of warfarin and introduced tecarfarin, a novel VKA, as a potential replacement. T...
No comment yet